Acutus Medical (AFIB)
OTHER OTC:AFIB
Top Page
Acutus Medical
(OTC:AFIB)
Select Model
Select Model
Rating:39Underperform
Price Target:
$0.00
▼(-100.00% Downside)
Action:ReiteratedDate:05/22/25
Acutus Medical's overall stock score is primarily impacted by its poor financial performance and valuation metrics. The company is unprofitable with negative cash flows and a highly leveraged balance sheet, posing significant investment risks. Technical analysis also indicates bearish momentum, further weighing on the stock's prospects.
Positive Factors
Innovative Product Offering
Acutus Medical's focus on innovative cardiac mapping systems positions it well in the growing electrophysiology market, offering potential for long-term growth through advanced medical technology.
Negative Factors
Financial Instability
Persistent financial instability with negative cash flows and high leverage poses significant risks to long-term viability, limiting the company's ability to invest in growth or weather downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Product Offering
Acutus Medical's focus on innovative cardiac mapping systems positions it well in the growing electrophysiology market, offering potential for long-term growth through advanced medical technology.
Read all positive factors
Acutus Medical (AFIB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.99K
Dividend YieldN/A
Average Volume (3M)20.94K
Price to Earnings (P/E)―
Beta (1Y)-40.60
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees85
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,912,306
10 Day Avg. Volume19,516
30 Day Avg. Volume20,944
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.14
Price to Sales (P/S)0.08
P/FCF Ratio-0.05
Enterprise Value/Market Cap7.27K
Enterprise Value/Revenue1.08
Enterprise Value/Gross Profit21.66
Enterprise Value/Ebitda9.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Acutus Medical Business Overview & Revenue Model
Company Description
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfol...
How the Company Makes Money
Acutus Medical generates revenue primarily through the sale of its medical devices and systems used in electrophysiology procedures. The company’s revenue model includes direct sales of its AcQMap® systems and disposable catheters to hospitals and...
Acutus Medical Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
30
Negative
Cash Flow
40
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.16M | 7.16M | 3.03M | 17.26M | 8.46M |
| Gross Profit | 1.01M | -3.14M | -1.91M | -15.66M | -7.42M |
| EBITDA | 2.25M | -5.33M | 35.20M | -105.12M | -92.55M |
| Net Income | -9.55M | -81.66M | -39.62M | -117.68M | -101.98M |
Balance Sheet | |||||
| Total Assets | 28.65M | 53.96M | 133.44M | 169.79M | 192.53M |
| Cash, Cash Equivalents and Short-Term Investments | 14.02M | 22.40M | 70.45M | 100.77M | 131.07M |
| Total Debt | 35.76M | 38.48M | 38.86M | 45.40M | 41.08M |
| Total Liabilities | 40.24M | 54.84M | 58.42M | 64.07M | 65.95M |
| Stockholders Equity | -11.59M | -879.00K | 75.02M | 105.73M | 126.58M |
Cash Flow | |||||
| Free Cash Flow | -31.77M | -63.34M | -89.02M | -109.66M | -96.39M |
| Operating Cash Flow | -31.66M | -63.12M | -85.03M | -99.68M | -85.17M |
| Investing Cash Flow | 22.15M | 58.55M | 104.75M | 19.07M | -63.82M |
| Financing Cash Flow | -2.89M | -2.66M | -12.12M | 79.57M | 164.43M |
Acutus Medical Risk Analysis
Acutus Medical disclosed 63 risk factors in its most recent earnings report. Acutus Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acutus Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $125.59M | ― | 476.59% | ― | 20.59% | 18.61% | |
50 Neutral | $50.20M | -2.73 | -2072.11% | ― | 27.90% | 1.62% | |
49 Neutral | $50.97M | -0.55 | 129.49% | ― | -25.18% | -9.71% | |
47 Neutral | $272.02M | ― | -122.17% | ― | 12.83% | -19.53% | |
45 Neutral | $62.81M | -1.01 | 1.02% | ― | -99.28% | -46.17% | |
39 Underperform | $2.99K | -0.03 | 406.89% | ― | ― | ― |
* Healthcare Sector Average
AFIB
Acutus Medical
0.01
-0.03
-75.00%
RCEL
Avita Medical
4.54
-4.09
-47.39%
CLPT
ClearPoint Neuro
8.96
-2.19
-19.64%
ECOR
Electrocore
6.65
1.13
20.47%
PAVM
PAVmed
9.75
-10.66
-52.23%
COCH
Envoy Medical
0.65
-0.61
-48.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.